Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 MIRACLE trial Recent EU approval from the European Medicines Agency (EMA) boosts ...

(Reuters) -The hot flashes and night sweats that plague breast cancer survivors during years-long hormone-suppressing therapy ...

Secured approval from the Regulation Agency for Medical and Pharmaceutical Activities (RAMPA) in Georgia for Phase 2B/3 ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial ("EMERALD-1”), ...

It is the latest U.S. firm to make the move, which includes the London office, easing the switch with a two-week August WFH ...

Denmark: Following a recent World Health Organization (WHO) alert on semaglutide-containing medicines, Novo Nordisk has ...

Johnson & Johnson (NYSE:JNJ) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On July 3, Janssen-Cilag, a ...

Stocktwits - Danish pharmaceutical company Novo Nordisk (CSE: NOVOb) (NVO) on Tuesday said that it has submitted an ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...